1.27
price down icon0.78%   -0.01
after-market 시간 외 거래: 1.28 0.01 +0.79%
loading
전일 마감가:
$1.28
열려 있는:
$1.28
하루 거래량:
112.26K
Relative Volume:
0.23
시가총액:
$3.19M
수익:
-
순이익/손실:
$-8.26M
주가수익비율:
-0.0237
EPS:
-53.609
순현금흐름:
$-12.17M
1주 성능:
-3.79%
1개월 성능:
-3.05%
6개월 성능:
-90.39%
1년 성능:
-96.19%
1일 변동 폭
Value
$1.23
$1.29
1주일 범위
Value
$1.20
$1.40
52주 변동 폭
Value
$1.10
$43.69

Gri Bio Inc Stock (GRI) Company Profile

Name
명칭
Gri Bio Inc
Name
전화
(619) 400-1171
Name
주소
2223 AVENIDA DE LA PLAYA, LA JOLLA
Name
직원
4
Name
트위터
Name
다음 수익 날짜
2024-11-12
Name
최신 SEC 제출 서류
Name
GRI's Discussions on Twitter

GRI을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
GRI
Gri Bio Inc
1.27 3.19M 0 -8.26M -12.17M -53.61
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
441.30 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
521.00 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
322.83 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
560.14 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
241.20 28.51B 3.81B -644.79M -669.77M -6.24

Gri Bio Inc Stock (GRI) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2024-12-09 개시 H.C. Wainwright Buy

Gri Bio Inc 주식(GRI)의 최신 뉴스

pulisher
Jun 14, 2025

Q2 Earnings Estimate for GRI Bio Issued By HC Wainwright - Defense World

Jun 14, 2025
pulisher
Jun 12, 2025

Kalkine : GRI Bio Advancing in the Nasdaq Composite Healthcare Space - Kalkine Media

Jun 12, 2025
pulisher
Jun 12, 2025

GRI Bio (NASDAQ:GRI) Receives “Buy” Rating from HC Wainwright - Defense World

Jun 12, 2025
pulisher
Jun 12, 2025

HC Wainwright Reiterates Buy Rating for GRI Bio (NASDAQ:GRI) - Defense World

Jun 12, 2025
pulisher
Jun 12, 2025

GRI Bio’s (GRI) Buy Rating Reiterated at HC Wainwright - Defense World

Jun 12, 2025
pulisher
Jun 12, 2025

GRI Bio (NASDAQ:GRI) Given “Buy” Rating at HC Wainwright - Defense World

Jun 12, 2025
pulisher
Jun 12, 2025

GRI Bio (NASDAQ:GRI) Earns Buy Rating from HC Wainwright - Defense World

Jun 12, 2025
pulisher
Jun 12, 2025

GRI Bio’s (GRI) “Buy” Rating Reaffirmed at HC Wainwright - Defense World

Jun 12, 2025
pulisher
Jun 11, 2025

# H.C. Wainwright REITERATES Buy rating on GRI Bio stock By Investing.com - Investing.com India

Jun 11, 2025
pulisher
Jun 11, 2025

# H.C. Wainwright REITERATES Buy rating on GRI Bio stock - Investing.com

Jun 11, 2025
pulisher
Jun 11, 2025

GRI Stock Maintains Buy Rating and $10 Price Target | GRI Stock News - GuruFocus

Jun 11, 2025
pulisher
May 28, 2025

GRI Bio (NASDAQ:GRI) Price Target Cut to $34.00 by Analysts at Ascendiant Capital Markets - Defense World

May 28, 2025
pulisher
May 27, 2025

GRI Bio: Ascendiant Capital Lowers Price Target to $34 | GRI Sto - GuruFocus

May 27, 2025
pulisher
May 27, 2025

GRI Bio: Ascendiant Capital Lowers Price Target to $34 | GRI Stock News - GuruFocus

May 27, 2025
pulisher
May 24, 2025

GRI Bio (NASDAQ:GRI) Trading Down 4% – Here’s Why - Defense World

May 24, 2025
pulisher
May 23, 2025

GRI Bio expands at-the-market offering capacity By Investing.com - Investing.com Nigeria

May 23, 2025
pulisher
May 23, 2025

GRI Bio Expands Share Offering Agreement - TipRanks

May 23, 2025
pulisher
May 23, 2025

GRI Bio expands at-the-market offering capacity - Investing.com

May 23, 2025
pulisher
May 22, 2025

GRI Bio (GRI) Shows Promising Preclinical Results in Pulmonary Fibrosis Treatment | GRI Stock News - GuruFocus

May 22, 2025
pulisher
May 22, 2025

GRI Bio Reports Positive Preclinical Data For GRI-0621 - Nasdaq

May 22, 2025
pulisher
May 22, 2025

GRI Bio (GRI) Shows Promising Preclinical Results in Pulmonary F - GuruFocus

May 22, 2025
pulisher
May 22, 2025

GRI Bio IncPhase 2A Study Results For GRI-0621 Expected In Q2 2025 - marketscreener.com

May 22, 2025
pulisher
May 22, 2025

GRI Bio reports progress in pulmonary fibrosis treatment By Investing.com - Investing.com India

May 22, 2025
pulisher
May 22, 2025

GRI Bio reports progress in pulmonary fibrosis treatment - Investing.com

May 22, 2025
pulisher
May 22, 2025

GRI Bio Presents Positive Pre-Clinical Data Demonstrating GRI-0621 Resolves Inflammation and Fibrosis in Bleomycin-Induced Fibrosis and Reiterates Promising Preliminary Phase 2a Clinical Results - The Manila Times

May 22, 2025
pulisher
May 22, 2025

GRI Bio Presents Positive Pre-Clinical Data Demonstrating - GlobeNewswire

May 22, 2025
pulisher
May 22, 2025

GRI Bio Advances in IPF Treatment with Promising Trial Results - TipRanks

May 22, 2025
pulisher
May 21, 2025

GRI Bio to Participate in the Virtual Investor Closing Bell Series - GlobeNewswire

May 21, 2025
pulisher
May 21, 2025

GRI Bio CEO Reveals Next Steps in NKT Cell Therapy Development at Virtual Investor Series - Stock Titan

May 21, 2025
pulisher
May 16, 2025

GRI Bio meets interim clinical trial enrollment goal for IPF therapy - Pulmonary Fibrosis News

May 16, 2025
pulisher
May 16, 2025

GRI Bio to Present at A.G.P.'s Annual Healthcare Company Showcase - The Manila Times

May 16, 2025
pulisher
May 16, 2025

GRI Bio CEO Reveals Latest Developments in Revolutionary NKT Cell Technology at Major Healthcare Conference - Stock Titan

May 16, 2025
pulisher
May 15, 2025

GRI Bio reports positive early trial data for IPF treatment By Investing.com - Investing.com India

May 15, 2025
pulisher
May 15, 2025

GRI: Q1 Financial Report Highlights and Future Prospects | GRI S - GuruFocus

May 15, 2025
pulisher
May 15, 2025

GRI Bio reports positive early trial data for IPF treatment - Investing.com

May 15, 2025
pulisher
May 15, 2025

GRI: Q1 Financial Report Highlights and Future Prospects | GRI Stock News - GuruFocus

May 15, 2025
pulisher
May 15, 2025

GRI Bio Reports First Quarter 2025 Financial Results and Confirms GRI-0621 Phase 2a IPF Trial on Track for 6-Week Interim Data in Q2 2025 and Topline Data in Q3 2025 - The Manila Times

May 15, 2025
pulisher
May 15, 2025

GRI Bio, Inc. Reports Positive Phase 2a Interim Safety and Biomarker Results for GRI-0621 in Idiopathic Pulmonary Fibrosis Treatment - Nasdaq

May 15, 2025
pulisher
May 15, 2025

GRI Bio, Inc. SEC 10-Q Report - TradingView

May 15, 2025
pulisher
May 15, 2025

GRI Bio Reports First Quarter 2025 Financial Results and - GlobeNewswire

May 15, 2025
pulisher
May 09, 2025

GRI Bio reports positive interim biomarker data in IPF study By Investing.com - Investing.com Nigeria

May 09, 2025
pulisher
May 08, 2025

GRI Bio’s Interim Biomarker Data Demonstrate Positive Trend - GlobeNewswire

May 08, 2025
pulisher
May 08, 2025

GRI Bio's Interim Biomarker Data Demonstrate Positive Trend Towards Anti-Fibrotic Effect Of GRI-0621 - marketscreener.com

May 08, 2025
pulisher
May 08, 2025

GRI Bio reports positive interim biomarker data in IPF study - Investing.com

May 08, 2025
pulisher
May 08, 2025

GRI Bio’s Interim Biomarker Data Demonstrate Positive Trend Towards Anti-Fibrotic Effect of GRI-0621 in First Twelve Patients of Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”) - Yahoo Finance

May 08, 2025
pulisher
May 07, 2025

GRI Bio Continues To Drive Enrollment In Ongoing Phase 2A Study Of GRI-0621 In Idiopathic Pulmonary Fibrosis - marketscreener.com

May 07, 2025
pulisher
May 07, 2025

GRI Bio Continues to Drive Enrollment in Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis (“IPF”) - GlobeNewswire

May 07, 2025
pulisher
May 07, 2025

GRI Bio Continues to Drive Enrollment in Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis ('IPF”) - The Manila Times

May 07, 2025
pulisher
May 02, 2025

GRI Bio (GRI) to Release Earnings on Friday - Defense World

May 02, 2025
pulisher
Apr 24, 2025

GRI Bio Inc (GRI) Stock: Uncovering a 52-Week Range and Trading Volume - investchronicle.com

Apr 24, 2025
pulisher
Apr 17, 2025

FY2025 Earnings Forecast for GRI Bio Issued By HC Wainwright - Defense World

Apr 17, 2025

Gri Bio Inc (GRI) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$20.50
price down icon 1.11%
$35.87
price up icon 1.70%
$20.60
price down icon 3.38%
$99.49
price down icon 2.21%
$106.72
price up icon 0.55%
biotechnology ONC
$241.20
price down icon 5.22%
자본화:     |  볼륨(24시간):